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Abstract
Growing evidence supports the hypothesis that narcolepsy with cataplexy is an autoimmune 
disease. Using genome-wide association (GWA) in narcolepsy patients versus controls, with 
replication and fine mapping across three ethnic groups (3406 individuals of European ancestry, 
2414 Asians, and 302 African Americans), we found a novel association between SNP rs2305795 
in the 3′UTR of the purinergic receptor subtype 2Y11 (P2RY11) gene and narcolepsy (p(Mantel 
Haenszel)=6.1×10-10; odds ratio 1.28; n=5689). The disease-associated allele is correlated with a 
3-fold lower expression of P2RY11 in CD8+ T lymphocytes (p=0.003) and natural killer (NK) 
cells (p=0.031) but not in other peripheral blood mononuclear cell (PBMC) types. The low 
expression variant is also associated with decreased P2RY11 mediated resistance to adenosine 
triphosphate (ATP) induced cell death in T lymphocytes (p=0.0007) and NK cells (p=0.001). 
These results identify P2RY11 as an important regulator of immune cell survival, with possible 
implications in narcolepsy and other autoimmune diseases.
Narcolepsy-cataplexy affects 1 in 2,000 individuals and is primarily caused by the loss of 
around 70,000 hypocretin (hcrt, also known as orexin) producing neurons in the 
hypothalamus1,2. The disease is associated with HLA-DQB1*06023, and the T cell receptor 
alpha locus (TRA@)4. Further, autoantibodies against Tribbles homolog 2 (Trib2), a protein 
expressed in hcrt cells, have recently been detected in the sera of recent onset narcoleptic 
patients5,6,7. These findings strongly suggest narcolepsy is caused by an autoimmune attack 
on the hypocretin neurons. This disease may thus offer a unique model to study immune 
surveillance of neurons, a topic of growing importance.
Following on our recently published GWA study of 807 narcolepsy-cataplexy patients 
versus 1,074 HLA DQB1*0602 positive controls, we conducted replication of 10 loci in 
1,525 individuals of European ancestry (594 cases and 931 controls). Single Nucleotide 
Polymorphisms (SNPs) for replication were selected as having P-values less than p= 5×10-6. 
A total of 18 SNPs, representing 10 genomic regions met this criterion (Supplementary 
Table 1). Of these only one, rs4804122, replicated strongly, being still significant after 
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Bonferroni correction for 18 markers (p<0.01, see Table 1 for nominal p value). This SNP is 
located downstream of P2RY11 on chromosome 19 in a region of high linkage 
disequilibrium (LD) spanning several genes (PPAN, P2RY11, EIF3G, and DNMT1, Figure 
1).
The last of these 18 markers is rs9275523 a SNP located between HLA-DQB1 and HLA-
DQA2 (p= 5.1×10-6; OR 0.59; MAF 0.071 in 799 cases, 0.116 in 1068 controls). 
Association with this marker is consistent with prior data indicating that the genetic 
influences of HLA on narcolepsy predisposition are not mediated solely through 
DQB1*0602 heterozygosity3. DQB1*0602 homozygotes or DQB1*0602/0301 
heterozygotes are, for example, at higher risk for narcolepsy compared to DQB1*0602 
heterozygotes in general, whereas DQB1*0602/0601, DQB1*0602/0501 and 
DQB1*0602/0603 are at decreased risk3,8. Heterodimerisation of DQA1*0102 and 
DQB1*0602 with other DQA1 and DQB1 alleles of the DQ1 group may explain these 
protective effects, by reducing abundance of the disease susceptibility DQA1*0102/
DQB1*0602 heterodimer9. The finding of a secondary association in the HLA-DQ locus was 
thus expected and further indicates a complex influence of HLA-DQ or other loci in high LD 
with HLA-DQ on narcolepsy. A recently published study also reported an association of a 
SNP located in the HLA-DQA2 region, rs2858884, with narcolepsy independent ofo 
DQB1*06028. In our initial GWA study sample of 1,881 individuals of European ancestry, 
rs2858884 had a nominal p-value of 0.013, an effect well below rs9275523 (Supplementary 
Table 1).
Our next step was to attempt replication of the new chromosome 19 association in other 
ethnic groups. Surprisingly, rs4804122 had no effect in 2,414 Asians and a small African 
American sample (Table 1). This led us to explore differential LD patterns for this marker 
across ethnic groups. Based on data from the International HapMap Project, we selected 5 
SNPs in high LD with rs4804122 in individuals of European ancestry but lower LD in 
Asians. One additional marker, rs3745601, a functional SNP located in P2RY11 previously 
reported to be associated with myocardial infarction and elevated levels of C-reactive 
protein10 was also genotyped, even though it is in low LD with rs4804122. These 6 SNPs 
were genotyped in 3,406 individuals of European ancestry (1,401 patients and 2,005 
controls), 2,414 Asians (1,130 patients and 1,284 controls), and 302 African Americans (113 
patients and 189 controls). A SNP located in the 3′ untranslated region (3′UTR) of the 
P2RY11 gene, rs2305795, showed the highest association with narcolepsy across all ethnic 
groups (Table 2 and Figure 1). The rs2305795 association was significant in individuals of 
European ancestry (p=3.1×10-7), Asians (p=0.025), and overall (p=3.7×10-9) after 
Bonferroni correction for the 6 fine typing markers in the replication sample. These findings 
identify this locus as a novel narcolepsy susceptibility factor (rs2305795 nominal p value = 
6.1×10-10; odds ratio 1.28). The replication across ethnic groups also illustrates the value of 
transethnic mapping in narcolepsy, as previously found for HLA and TCR@ studies3,4,11. 
No significant interaction was found between rs2305795 and previously identified loci (data 
not shown).
To determine whether the presence of the disease associated SNP was correlated with a 
significant change in expression of any of the genes in the linkage region (Figure 1), we 
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quantified mRNA expression in peripheral blood mononuclear cells (PBMCs) of PPAN, 
P2RY11, PPAN-P2RY11, EIF3G and DNMT1 in a Caucasian sample of 60 narcoleptic and 
56 control subjects. Expression of P2RY11 mRNA correlated strongly with rs2305795 
genotype (2-fold lower expression with the disease associated allele, p=0.002, Figure 2A), 
sex (lower in females, p=0.039), but not disease status, HLA-DQB1*0602 genotype, age, or 
body mass index (BMI). The lack of effect of disease status is not surprising considering the 
current narcolepsy-cataplexy model suggesting rapid hypocretin cell destruction with 
minimal residual immune response once the destruction is complete (a “hit and run” 
hypothesis). A weaker correlation was also found with DNMT1 mRNA expression (lower 
with disease associated allele, p=0.029). As expression of DNMT1 positively correlates with 
P2RY11 independently of rs2305795 (R2=0.48, p<0.0001), this effect is likely secondary. 
Expression of the readthrough PPAN-P2RY11 transcript12 was found to be very low (15.5 
fold lower than P2RY11 expression) and to vary with sample storage conditions, thus was 
not further analyzed. Gene expression levels of PPAN and EIF3G did not correlate 
significantly with rs2305795 or disease status (Supplementary Table 2). These results 
indicate that rs2305795A, the disease-associated allele, decreases P2RY11 mRNA 
expression in PBMCs.
P2RY11 is a member of a large family of more than 20 purinergic receptors. Purinergic 
signaling plays a fundamental role in immune regulation, modulating proliferation, 
apoptosis, and chemotaxis in lymphocytes, monocytes, and polymorphonuclear 
granulocytes13,14. Unlike most other purinergic receptors, P2YR11 is a low affinity receptor 
and detects high concentrations of extracellular ATP. P2RY11 is unique among purinergic 
receptors, as it is coupled to both Gq and Gs, with activation leading to increases in both 
cAMP and IP315. In healthy tissue, ATP is mostly localized intracellularly (mM range) and 
not extracellularly (nM range). During inflammation, however, ATP levels rise in the 
extracellular space16 and produce a cascade of concentration-dependent effects on the 
immune system. At lower concentrations, ATP induces immune cell chemotaxis through the 
stimulation of P2Y2 and P2Y6 receptors17,18,19. High levels of ATP are typically cytotoxic, 
an effect mediated by the P2X7 receptor20,21,22,23. Because P2RY11 is a pseudogene in 
rodents, it has been difficult to study its function. P2RY11 expression is widespread, 
pronounced in both human brain and white blood cells24. In neutrophils, stimulation of 
P2RY11 delays apoptosis25, and P2RY11 has also been shown to inhibit the migratory 
capacity of monocyte-derived dendritic cells (MoDCs) and Cd1a+ dermal DCs26. In addition 
to the lack of P2RY11 in rodents, functional studies have also been hampered by a lack of 
specific ligands. Most studies have used NF157, a partially selective antagonist27. Only 
recently have a more specific antagonist (NF340) and an agonist (NF546) been developed28.
To further explore how P2RY11 might regulate the immune system, we next quantified 
receptor expression in CD4+ T cells, CD8+ T cells, CD56+ natural killer (NK) cells, CD19+ 
B cells, CD14+ monocytes, and myeloid/plasmacytoid dendritic cell (DC) subsets (a 
combination of CD1c+, CD141+, and CD304+ cells). P2RY11 expression has previously 
been shown to be higher in DCs compared to monocytes and CD4+ T cells29, but in that 
study expression in CD8+ and CD19+ cells was not measured. We found that P2RY11 
expression is widespread in immune cells but notably higher in CD8+ cells compared to DCs 
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(2.7-fold lower), CD19+ B cells (2.9-fold lower), CD4+ T cells (4-fold lower), and CD14+ 
monocytes (6.6-fold lower). Further, the effect of the disease associated allele, rs2305795A, 
on gene expression was apparent in both CD8+ T cells and NK cells (3-fold reduction across 
genotypes, Figure 2B), but not in other PBMC subtypes. The smaller genotype effect on 
expression in PBMCs (Figure 2A) is consistent with a primary effect in CD8+ T cells and 
NK cells, which represent roughly 25% of total PBMCs.
As changes in gene expression do not necessarily translate into differential functional 
effects, we next studied whether ATP and P2RY11 has genotype-dependent effects on 
immune cells. As previously reported12, we found that increasing concentrations of ATP 
induce PBMC cell death (Figure 3A), an effect likely mediated by P2X7 receptor 
stimulation. Using the recently developed P2RY11 agonist NF546 and antagonist NF340, 
we further discovered that P2RY11 stimulation mitigates this effect, suggesting that immune 
cell death in the presence of high ATP is controlled by a balance of activation of multiple 
purinergic receptors that includes P2RY11. A similar survival effect of P2RY11 stimulation 
by ATP has been reported in neutrophils24, and endothelial cells following NK cell mediated 
killing30. Comparing cells with various rs2305795 genotypes, we found that the protecting 
effect of P2RY11 stimulation was less pronounced in subjects carrying the narcolepsy-
associated, low expression rs2305795A genotype, as demonstrated by the lower P2RY11 
induced survival in PBMCs of this genotype (Figure 3B). To determine whether these 
effects vary by immune cell subsets, we used fluorescence activated cell sorting (FACS) and 
found significant genotype effects in NK (p=0.001), CD8+ T (p=0.0007) and CD4+ T cells 
(p=0.009), but not in monocytes or B cells (Figure 4). This result is in line with expression 
data reported in Figure 2B, although we also found genotype-dependent effects in CD4+ T 
cells, a population without P2RY11 expression differences, a finding possibly reflecting 
differential P2RY11 responses in various CD4+ T cell subsets.
How could reduced P2RY11 function, associated with rs2305795A, be involved in 
narcolepsy susceptibility? Our results demonstrate clear effects of the polymorphism on 
immune cell viability. A possible pathway may thus be modulation by P2RY11 of immune 
response to an important infectious trigger, such as Streptococcus Pyogenes31, or a 
modulatory effect of the autoimmune process leading to hypocretin cell destruction. 
Although our results suggest a novel function for P2RY11 in T cells and NK cells, relevant 
effects on other cells not measured here are possible, if not likely. For example, P2RY11 
induces thrombospondin-1 secretion and inhibits lipopolysaccharide-stimulated 
interleukin-12 (IL-12) release in monocyte-derived DCs32, an effect that could have a 
cascade of indirect effects on the immune system. Further, activation of P2RY11 on DCs 
induces maturation and stimulates IL-8 release33. As IL-8 is an important mediator of 
neutrophil chemotaxis, modulation of the innate immune system could also be involved. 
Indeed, it has recently been shown that P2RY11 stimulation modulates NK cell chemotaxis 
in response to CX(3)CL1 and CXCL1230. Finally, direct effects of P2RY11 on hypocretin 
cell apoptosis or microglial activation are also possible as virtually nothing is known 
regarding localized expression and function of P2RY11 in the human brain.
In summary, we report on a novel association of P2RY11 and rs2305795A in narcolepsy. 
This receptor is highly expressed in CD8+ T cells and NK cells, and modulates immune cell 
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Narcolepsy-cataplexy cases were selected as previously described4. The initial GWA sample 
was comprised of 807 cases and 1,074 Caucasian DQB1*0602 positive controls: 415 cases 
and 753 controls were recruited from the United States and Canada; 392 cases and 321 
controls were recruited from European centers. Analysis of the GWA data (549,596 SNPs) 
was performed as previously described4. The Caucasian replication sample contained 1526 
individuals, of whom 1195 were recruited from the United States and Canada (404 cases, 
791 controls) and 331 from Europe (211 Cases, 120 controls). The Asian sample included 
1269 Chinese (588 cases, 681 controls), 869 Japanese (437 cases, 432 controls), and 276 
Koreans (105 cases, 171 controls). Finally, we studied 302 African Americans (113 cases, 
189 controls). Interaction studies were conducted in the initial set and in replication sets 
(cases and controls) using a test for epistatic effects implemented in the PLINK software 
package (v1.06 26/April/2009), which performs a logistic regression including main 
genotype effects plus an interaction term.
Fine mapping of the chromosome 19 locus, and replication of published SNPs
For fine mapping of the associated locus, we used the same case and control samples as 
described above. Based on LD and r2 data from the International HapMap Project 
(Hapmap.org), we chose 5 markers in high LD with our initial hit in individuals of European 
ancestry but lower linkage in other ethnic groups. The chosen SNPs were rs11666402, 
rs12460842, rs2305795, rs11880388, and rs2228611. We also typed the potential functional 
SNP rs3745601 in P2RY11. Previously reported SNP rs2858884 was also genotyped for 
replication in our sample. For the genotyping we used predesigned Taqman SNP genotyping 
assays (Applied Biosystems, Carlsbad, CA, USA). Standard D′/LOD plots were generated 
using Haploview 4.2. Genotyping was performed at Stanford University except for Chinese 
samples, which were genotyped at Beijing University by one of us (LL).
Selection of cells for mRNA expression analysis
To compare mRNA expression in controls and narcoleptic subjects, 116 subjects (60 
patients and 56 controls) were randomly selected. Twenty-four controls were added on the 
basis of their rs2305795 genotype (age, sex and gender matched within genotypic groups). 
PBMCs were purified using Ficoll-Hypaque gradient centrifugation, total RNA isolated 
from ∼4×106 cells (RNeasy Mini Kit #74104, QIAGEN), and RNA concentration/quality 
determined by absorbance at 260 and 280 nm (SpectraMax M2e, Molecular Devices). In the 
24 subjects selected by genotype, ∼ 1×107 PBMCs were sequentially sorted based on CD4, 
CD8, CD14, and CD19 positivity using Dynabeads (Invitrogen Dynal AS, Oslo, Norway). 
Two independent replications were performed. In the first, CD19 was separated first, 
followed by CD14, CD4, and CD8. In the second, CD14 was separated first, followed by 
CD8, CD4, and CD19. CD8+ T cells and NK cells were separated independently from new 
sets of ∼1×107 PBMCs. In this experiment, NK cells were purified using MACS CD56+ 
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MicroBeads (NK cell Isolation Kit #130-092-657, Miltenyi Biotec, Bergisch Gladbach, 
Germany) while CD8+ T-cells were purified from the CD56- fraction (CD8+ T Cell Isolation 
Kit #130-091-154, Miltenyi Biotec, Bergisch Gladbach, Germany). Finally, for purification 
of dendritic cells, we performed negative selection using Dynabeads Human DC Enrichment 
Kit (Invitrogen Dynal AS, Oslo, Norway) followed by positive selection using Blood 
Dendritic Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) on ∼1×108 
PBMCs from 21 healthy control blood samples of the 3 genotypes. Purity of the cell 
fractions was addressed by quantitative RT-PCR of the different cell surface marker mRNAs 
(see below) and also a smaller sample was sorted using flow compatible Dynabeads 
(#113.61D, #113.62D, #113.67D, and #125-06D, Invitrogen Dynal AS, Oslo, Norway) and 
checked by flow cytometry as described below. The MACS Microbead sorted fractions was 
checked directly with flow cytometry. Purities of the fractions were (mean ± SD): CD4: 
97.6% ± 0.4; CD8: 98% ± 1.2; CD14: 92.3% ± 5.9; CD19: 76.1% ± 11.2; CD56: 89.6% ± 
4.9.
Gene expression using Real-Time (RT) PCR
cDNA was synthesized from 200 ng total RNA (cell subsets) or 400 ng total RNA (PBMCs) 
using High Capacity cDNA Reverse Transcription Kit (#4374966, Applied Biosystems). 
Gene expression was determined by RT-PCR (ABI 7000, Applied Biosystems) using 
TaqMan gene expression assays (Applied Biosystems). Probe numbers were P2RY11 
(Hs01038858_m1), PPAN (Hs00220301_m1), PPAN-P2RY11 (Hs01568729_m1), EIF3G 
(Hs00959170_m1), DNMT1 (Hs00945899_m1), CD4 (Hs00181217_m1), CD8 
(Hs00233520_m1), CD14 (Hs00169122_g1), CD19 (Hs00174333_m1), CD56 
(Hs00941830_m1), CD1c (Hs00233509_m1), BDCA-2/CD303 (Hs00369958_m1), NRP1/
CD304 (Hs00826128_m1), B2M (#4333766F), UBC (Hs00824723_m1), GAPDH 
(#4333764F), and ACTB (#4333762F), the latter four serving as endogenous control genes. 
RT-PCR of CD4, CD8, CD14, CD19, CD56, CD1c, CD303, and CD304 mRNAs were used 
to verify purity of each sorted cell fraction and samples. Cell fractions had a 30-69000 fold 
difference in expression between wanted and unwanted markers, except CD19 cells where 
differences were 12-24 fold and dendritic cells where differences where 5.5-27 fold. 
Relative quantities of target mRNAs were calculated using the comparative threshold 
method (Ct-method), with the geometric mean of UBC, GAPDH, and ACTB expression as 
endogenous controls. Standard deviations (SD) on fold changes were calculated as 
SD=2ΔΔCt·ln2·SD(ΔCt) with SD(ΔCt) being the SD of ΔCt of all samples in the group.
ATP induced cell death
PBMCs (1×106 cells/ml) from twelve controls selected on the basis of their rs2305795 
genotype (age, sex and gender matched between genotypic groups) were incubated 1 or 2 
hours in the presence of ATP in different concentrations (0.1, 1, 10, 100 μM), combined 
with NF546 (0.1, 1, 10, 100 μM) and/or NF340 (0.1, 1, 10 μM) (both compounds were 
synthesized as described previously27,28). Both compounds were also tested alone (NF546 
0.1, 1, 10, 100, and 500 μM; NF340 0.1, 1, 10, and 100 μM), and no effect was seen on cell 
viability except a tendency to a decrease with 1 μM NF546. All cell work was performed 
using Ultra Low Attachment plates (24W: #3473, 96W: #7007, Costar, Corning Inc., 
Corning, NY), and care was taken to flush loosely attached cells of the plates for analysis. 
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The cells were counted in a hemocytometer using Trypan Blue exclusion of dead and dying 
cells. All measurements were performed in duplicates. In a second setup all surviving cells 
were subsequently analysed by FACS to determine their immune phenotypes.
FACS analysis of cell phenotypes
Purity of the different cell fractions were checked on a FACscan using the following 
antibody combinations (antibodies are from BD Biosciences, San Jose, CA). 1) αCD14-
FITC (#555397) and αCD4-PerCP-Cy5.5 (#560650) 2) αCD8-FITC (#555366), αCD56-PE 
(#555516), and αCD3-PerCP, 3) αCD19-PE (#555413) and αCD3-PerCP. For analyzing the 
phenotypes of the PBMCs surviving the ATP treatment we used a 7-marker panel consisting 
of: αCD14-FITC (#555397), αCD4-PerCP-Cy5.5 (#560650), αCD3-Pacific Blue 
(#558117), αCD19-APC (#555415), αCD56-PE (#555516), and αCD8-PE-Cy7 (#557746) 
also including Aqua Amine Live/Dead cell stain (L34957, Invitrogen). This analysis was 
performed on a BD LSRII (BD Biosciences) in duplicates. Data was combined with cells 
counts as described above.
Statistical analysis
Genotype data was maintained in our database (Progeny Lab 7). Allelic tests of association 
were performed using the PLINK software package (v1.06 26/April/2009). Genome wide 
association analysis of the original Affymetrix sample has been described previously4. 
When studying multiple ethnic groups or subgroups (Taiwanese, Chinese, Japanese, 
Koreans) the Mantel Haenszel test was used together with the Breslow Day test of 
homogeneity of the Odds Ratio. For statistical analysis of expression data, we used student 
T-test, one- and two-way ANOVAs in GraphPad Prism Version 5.00 where appropriate, and 
general linear regression models in Systat 12 Version 12.00.08, with control of relevant 
covariates (age, sex, BMI), if significant.
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Risk locus on 19q13.2, showing gene organization and linkage disequilibrium in the region 
of interest (10,071,000-10,130,000). Top: D′/LOD-based LD plot using data from combined 
Chinese and Japanese populations (CHB-JPT). Bottom: D′/LOD-based LD plot for 
individuals of European ancestry only (CEU-TSI). D′ values are calculated from HapMap 
v3R2 CHB, JPT, CEU, and TSI populations. In addition, r2 values between the original 
marker, rs4804122 (green) and the best transethnic marker rs2305795 (orange) derived from 
our own data are indicated. rs2305795 falls in the 3′UTR of P2RY11.
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P2RY11 mRNA expression in peripheral blood mononuclear cells (PBMCs). A) Expression 
in PBMCs from 116 subjects with various rs2305795 genotypes (Mean + SEM, 60 patients 
and 56 controls; AA n=49, AG n=51, GG n=16). As no direct effect of disease status on 
P2RY11 expression was observed, subjects are grouped by genotype. The P2RY11 
rs2305975AA genotype results in a 50% reduction in P2RY11 expression compared to the 
rs2305795GG genotype and is associated with increased risk of narcolepsy. B) P2RY11 
expression by rs2305795 genotype in various immune cell subsets (Mean + SEM, n=7-8 
normal controls per genotype category). NK cells= CD56+ natural killer cells; B Cells = 
CD19+ B cells; Monocy.=CD14+ monocytes; DCs=myeloid/plasmacytoid dendritic cells. 
Shown are Bonferroni corrected one-way ANOVA p-values.
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PBMC cell death induced by ATP is inhibited by the stimulation of P2RY11 and varies by 
rs2305795 genotype. A) Effect of ATP on cell viability and dose-response of co-incubation 
with the P2RY11 specific agonist NF546 and antagonist NF340 (Mean + SEM, n= 7-8, 
rs2305795AG control subjects). Overall one-way ANOVA p-values are shown, with 
Tukey's post test: * significantly different from control with no ATP, p<0.01; # significantly 
different from treatment with 100 μM ATP but no NF546, p<0.01; $ significantly different 
from treatment with 100 μM ATP and 100 μM NF546, p<0.01. B) Effect of the rs2305795 
genotype on the percent of cells rescued from ATP induced cell death by P2RY11 
stimulation. 10 μM NF546 has a less potent effect on cell survival after ATP-induced cell 
death with the rs2305795AA genotype compared to the rs2305795GG genotype. 
Heterozygote subjects fall in between. Mean + SEM, n=9 subjects in each group.
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Effect of ATP and P2RY11 co-stimulation on different immune cell subtypes. PBMCs were 
co-incubated with 100 uM ATP and the P2RY11 specific agonist NF546 in different doses 
and the effect on different cell fractions was determined by FACS. An effect by rs2305795 
genotype was seen in T lymphocytes and NK cells but not in B lymphocytes and monocytes. 
Shown are mean + SEM, n=8/column, p-values are from one-way ANOVAs.
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